Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : U.S. CDC advisers weigh Moderna, J&J COVID-19 vaccine boosters, mix-and-match shots

10/21/2021 | 12:44pm EST

Oct 21 (Reuters) - A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Thursday are considering several recommendations for rollout of COVID-19 vaccine boosters from Moderna Inc and Johnson & Johnson , expected to pave the way for additional shots for millions of Americans.

The U.S. Food and Drug Administration on Wednesday authorized the booster doses U.S. FDA clears Moderna, J&J COVID-19 boosters, backs use of different vaccine for boost, and said Americans can choose a different shot from their original inoculation.

The CDC is expected to sign off in the coming days on the recommendations of the panel for a rollout that health officials said could be confusing.

In a nod to the advisory panel's task ahead, CDC Director Dr. Rochelle Walensky laid out its charge in helping clarify any confusion about the various booster regimens.

"These recommendations will not just address who should receive a booster dose, but also include what vaccine they should receive," she said at the start of the meeting.

The panel is set to vote on booster dose recommendations later on Thursday, which will be sent to Walensky for review.

The FDA and CDC previously signed off on booster shots of the COVID-19 vaccine from Pfizer Inc and partner BioNTech SE for those age 65 and over, as well as individuals at high risk or severe illness and those at risk of exposure to the virus through their jobs.

(Reporting by Manas Mishra in Bengaluru and Julie Steenhuysen in Chicago; Editing by Bill Berkrot)


ę Reuters 2021
All news about MODERNA, INC.
11/26Vaccine companies testing efficacy against COVID-19 Omicron variant
AQ
11/26Moderna to Test Variant-Specific Vaccine Candidate
DJ
11/26Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
BU
11/26ADRs Close Lower; BioNTech Rises, Carnival Drops
DJ
11/26US Stocks, Treasury Yields Sink With Crude Oil as Concern Mounts Over New COVID-19 Stra..
MT
11/26CLOSE UPDATE : US Stocks, Treasury Yields Sink With Crude Oil as Concern Mounts Over New C..
MT
11/26Delta, Carnival fall; Moderna, Clorox rise
AQ
11/26Stocks tumble on new coronavirus variant fear
RE
11/26Covid-19 Vaccine Maker Stocks Higher Amid Variant Concerns
DJ
11/26FDA Places Clinical Hold on Phase 3 Study for Ocugen COVID-19 Vaccine Covaxin
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 449 M - -
Net income 2021 11 170 M - -
Net cash 2021 12 747 M - -
P/E ratio 2021 12,5x
Yield 2021 -
Capitalization 134 B 134 B -
EV / Sales 2021 6,93x
EV / Sales 2022 5,38x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Last Close Price 329,63 $
Average target price 272,53 $
Spread / Average Target -17,3%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431
ALNYLAM PHARMACEUTICALS, INC.45.06%22 548